CLINICAL TRIALS PROFILE FOR CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

All Clinical Trials for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00158587 ↗	Eight Week Primaquine Regimen for the Treatment of Vivax Malaria	Completed	HealthNet TPO	Phase 3	2004-04-01	Plasmodium vivax represents a major health problem throughout the tropics. Outside Africa it accounts for over 50% of cases, affecting an estimated 70-80 million people per year. A substantial proportion of clinical cases are not caused by infective bites of Anopheles spp, but by activation of latent hypnozoites in the liver. These relapses may significantly impede development since each illness may result in 5-15 days of absence from work or school. Primaquine(PQ) is the only drug available that eliminates hypnozoites, though its use is beset by clinical problems; it may precipitate haemolytic anaemia in individuals deficient in the blood enzyme glucose 6 phosphate dehydrogenase (G6PD). Without affordable G6PD testing, primaquine use is precluded. Evidence suggests, however, that a course of 8 weekly doses may be a safe and effective alternative to the traditional 14 day course of the drug. The aim of the proposed study, therefore, is to test whether 8 weekly doses of primaquine is as effective as the 14 day course at preventing relapse malaria, without the risk of hemolysis in G6PD deficient individuals.
NCT00158587 ↗	Eight Week Primaquine Regimen for the Treatment of Vivax Malaria	Completed	Gates Malaria Partnership	Phase 3	2004-04-01	Plasmodium vivax represents a major health problem throughout the tropics. Outside Africa it accounts for over 50% of cases, affecting an estimated 70-80 million people per year. A substantial proportion of clinical cases are not caused by infective bites of Anopheles spp, but by activation of latent hypnozoites in the liver. These relapses may significantly impede development since each illness may result in 5-15 days of absence from work or school. Primaquine(PQ) is the only drug available that eliminates hypnozoites, though its use is beset by clinical problems; it may precipitate haemolytic anaemia in individuals deficient in the blood enzyme glucose 6 phosphate dehydrogenase (G6PD). Without affordable G6PD testing, primaquine use is precluded. Evidence suggests, however, that a course of 8 weekly doses may be a safe and effective alternative to the traditional 14 day course of the drug. The aim of the proposed study, therefore, is to test whether 8 weekly doses of primaquine is as effective as the 14 day course at preventing relapse malaria, without the risk of hemolysis in G6PD deficient individuals.
NCT00158587 ↗	Eight Week Primaquine Regimen for the Treatment of Vivax Malaria	Completed	London School of Hygiene and Tropical Medicine	Phase 3	2004-04-01	Plasmodium vivax represents a major health problem throughout the tropics. Outside Africa it accounts for over 50% of cases, affecting an estimated 70-80 million people per year. A substantial proportion of clinical cases are not caused by infective bites of Anopheles spp, but by activation of latent hypnozoites in the liver. These relapses may significantly impede development since each illness may result in 5-15 days of absence from work or school. Primaquine(PQ) is the only drug available that eliminates hypnozoites, though its use is beset by clinical problems; it may precipitate haemolytic anaemia in individuals deficient in the blood enzyme glucose 6 phosphate dehydrogenase (G6PD). Without affordable G6PD testing, primaquine use is precluded. Evidence suggests, however, that a course of 8 weekly doses may be a safe and effective alternative to the traditional 14 day course of the drug. The aim of the proposed study, therefore, is to test whether 8 weekly doses of primaquine is as effective as the 14 day course at preventing relapse malaria, without the risk of hemolysis in G6PD deficient individuals.

Clinical Trial Conditions for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

Condition Name

Condition Name for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE
Intervention	Trials
Malaria	6
Malaria, Vivax	4
Vivax Malaria	4

Condition MeSH

Condition MeSH for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE
Intervention	Trials
Malaria	13
Malaria, Vivax	10
Glucosephosphate Dehydrogenase Deficiency	2

Clinical Trial Locations for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

Trials by Country

Trials by Country for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE
Location	Trials
Thailand	7
Brazil	5
Indonesia	5
Ethiopia	4
Vietnam	3

Clinical Trial Progress for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

Clinical Trial Phase

Clinical Trial Phase for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	6
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE
Clinical Trial Phase	Trials
Completed	14
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

Sponsor Name

Sponsor Name for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE
Sponsor	Trials
University of Oxford	6
Medicines for Malaria Venture	4
GlaxoSmithKline	3

Sponsor Type

Sponsor Type for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE
Sponsor	Trials
Other	37
Industry	4
U.S. Fed	1

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE Market Analysis and Financial Projection

Last updated: April 24, 2026

Chloroquine Phosphate + Primaquine Phosphate: Clinical Trial Signal, Market Readout, and 5-Year Projection

What is the current clinical-trial landscape for the combination?

The combination of chloroquine phosphate (CQ) and primaquine phosphate (PQ) is not tracked as a single, global “fixed combination product” in modern registries at the intensity seen for newer antimalarials. Current clinical-trial activity is dominated by (i) newer partner therapies and ACTs, and (ii) reinforcement studies in targeted indications (notably malaria transmission stages and relapse biology), often using chloroquine and/or primaquine separately or under protocolized use rather than branded combination.

Implication for pipeline readouts: the market is driven more by proven regimen utility and guideline positioning (where chloroquine remains relevant due to resistance geography and drug availability) and by primaquine's gametocytocidal and relapse-preventive role than by a steady stream of late-stage combination trials.

Net clinical signal to underwriting teams: treat the CQ + PQ regimen as a low-innovation, guideline-dependent therapy rather than an emerging pipeline product. That affects how investors price future exclusivity and lifecycle value.

---

What are the practical clinical endpoints that keep CQ + PQ relevant?

Across malaria programs, CQ and PQ are used for different parasite-stage objectives:

• Chloroquine phosphate (CQ):

  • Targets erythrocytic asexual parasites (blood-stage disease).
  • Clinical outcomes are typically parasite clearance time, PCR-corrected adequate clinical and parasitological response (ACPR), and recrudescence rates.

• Primaquine phosphate (PQ):

  • Targets gametocytes (transmission blocking) and is used for radical cure against hypnozoites in P. vivax/P. ovale (when indicated and safe).
  • Clinical outcomes typically include gametocyte clearance, relapse rates, and hemolysis/safety metrics with G6PD activity testing.

Why this matters for a market projection: guideline adoption hinges on stage coverage (blood + transmission/relapse) and safety feasibility (G6PD access). Where G6PD testing is not available, deployment may shrink even if efficacy is intact.

---

How does the market position today’s CQ + PQ use?

1) Product status

• CQ and PQ are long-established generics in many geographies.
• Pricing and availability are governed by local procurement, donor-funded programs, and national malaria control plan selection rather than premium IP-driven competition.

2) Resistance geography and regimen substitution

• CQ use is limited by chloroquine resistance prevalence. In many settings, ACTs displace CQ.
• Primaquine has broad utility but deployment is constrained by G6PD testing access and safety protocols (including population eligibility rules).

3) Channel economics

• The dominant buyer is government and global health procurement channels.
• Contracts reward supply reliability and cost per treatment, not clinical novelty.

Result: the “market” is less about new-to-market adoption and more about retained volume in regions where chloroquine remains a viable blood-stage option plus primaquine use where transmission blocking and radical cure are needed and feasible.

---

What is the addressable demand base for CQ + PQ?

A credible demand model must anchor to malaria epidemiology and treatment policy. The high-level structure is:

1. Malaria incidence volume by region
2. Share of cases where chloroquine remains recommended or used
3. Share of cases where primaquine is indicated
4. Eligibility adjustment due to G6PD testing constraints
5. Forecasted procurement volumes

Because CQ and PQ are generics, market value is sensitive to:

• unit price trajectories (tender-driven),
• formulation (oral vs alternative),
• packaging and dosing standards (adult vs pediatric dosing logic),
• and substitution with ACTs.

---

What does a scenario-based 5-year market projection look like?

Below is a business projection framework (not a clinical efficacy claim) designed for an underwriting lens. It assumes:

• no major regulatory IP moat emerges,
• no replacement by a new CQ + PQ combination with exclusivity,
• and procurement behavior follows national guideline updates.

Assumptions used for projection math

• Base-year demand: tied to “retained use” segments where CQ is still used for uncomplicated malaria and PQ is deployed for indicated stages.
• Annual volume change: declines as ACT penetration rises, partially offset by continued primaquine need.
• Annual price change: generics pricing is pressured by tenders and competition, with modest variability.

5-year projection (directional)

Year	Expected volume trend	Expected net price trend	Net market value trend
2026	Slight decline	Flat to down	Mild decline
2027	Moderate decline	Down	Moderate decline
2028	Moderate decline	Down	Moderate-to-steep decline
2029	Stabilization in residual markets	Flat to slightly down	Low single-digit decline
2030	Slow residual erosion	Flat	Stable-to-low decline

Range framing for business decisions

• Upside case: slower guideline replacement of CQ in specific geographies; improved G6PD testing rollout supports PQ eligibility.
• Downside case: faster ACT substitution and tighter safety administration reduces PQ eligibility where testing is absent.

For capital planning, treat this as a value-contraction market with pockets of durability.

---

How should R&D teams interpret “clinical trials updates” for these drugs?

Even where trials exist, the strategic question for development teams is whether studies support:

• new dosing strategies that change procurement rules,
• improved safety implementation (especially G6PD pathways),
• or expanded indications (rare for these legacy compounds).

Commercial conclusion: R&D resources should be directed to evidence that changes deployment policy, not to incremental efficacy studies that do not shift guideline inclusion.

---

What regulatory and policy constraints matter most for market realization?

Primaquine-specific constraints

• G6PD testing requirements drive eligibility.
• Safety labeling and contraindication rules can reduce eligible patient share if testing lags.

Chloroquine-specific constraints

• Regional resistance changes national guideline recommendations.
• Substitution with ACTs reduces eligible share.

---

Key takeaways for business planning

• Clinical activity is unlikely to re-rate these assets as IP-driven growth products; the market behaves as a guideline- and procurement-led generics segment.
• Primaquine demand is structurally supported by transmission-blocking and radical cure needs, but G6PD testing capacity is the limiting factor.
• Chloroquine demand is geographically constrained by resistance; ACT substitution is the main volume headwind.
• 5-year outlook is contraction with residual durability, not expansion: expect low-to-moderate erosion in market value with stabilization in pockets where CQ remains in use and PQ eligibility improves.

---

FAQs

1) Is chloroquine phosphate + primaquine phosphate considered a modern combination pipeline by regulators?

No. Market and clinical use are governed by established roles and guideline pathways for CQ (blood-stage) and PQ (transmission/relapse), with generics deployment dominating.

2) What is the main limiter for primaquine uptake in practice?

G6PD testing access and eligibility rules, which directly affect treatable population size.

3) Why does chloroquine market volume decline even if malaria incidence stays high?

Because chloroquine resistance drives guideline substitution toward ACT regimens in many regions.

4) What type of clinical evidence would most change market share for CQ + PQ?

Evidence that changes national policy on either (i) CQ regimen eligibility in resistant geographies or (ii) safe, scalable PQ administration with operational G6PD workflows.

5) What commercial strategy fits a contracting generics market?

Focus on procurement readiness, supply reliability, tender compliance, and delivery programs that improve PQ eligibility execution, rather than pipeline bets on new IP exclusivity.

---

References

[1] World Health Organization (WHO). Guidelines for malaria treatment and updates on antimalarial dosing and use policies. WHO malaria guidance portal.
[2] WHO. WHO model lists and evidence guidance related to malaria medicines and safety considerations for primaquine use (including G6PD testing policy). WHO malaria guidance portal.